FDA proposes cutting off affordable GLP-1 access for millions
A move by the U.S. Food and Drug Administration could significantly change how millions of Americans access some of the most widely used weight loss medications on the market. On April 30, the FDA announced a proposal to remove glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy and […]
GLP-1 weight loss drugs may be sparing muscle more than anyone expected
A review of 36 studies on GLP-1 medications suggests most of the weight lost comes from fat, not muscle, offering some reassurance to the millions now using these drugs. GLP-1 medications have moved from niche diabetes treatment to one of the most prescribed drug categories in the country in a remarkably […]